Skip to main content
Premium Trial:

Request an Annual Quote

Celera Genomics And Rhone-Poulenc Rorer Enter Target Discovery Alliance

Premium

ROCKVILLE, Md.--Celera Genomics announced a three-year gene discovery agreement with Rhone-Poulenc Rorer, the pharmaceutical subsidiary of Rhone-Poulenc, to identify therapeutic targets by applying Celera's proprietary GeneTag technology to Rorer's disease model systems. GeneTag is a global gene expression profiling technology that provides a rapid, quantitative measurement of all RNA transcripts present in a cell or tissue. According to Celera, it is capable of detecting rare and novel transcripts in quantities less than one copy per cell and enables researchers to quickly focus on genes relevant to the specific disease model, biological pathway, or drug response under investigation. Rorer will pay up-front fees, milestones, and royalties to Celera in connection with commercialization of any drugs resulting from the alliance. In addition, Rorer has the option to access Celera's capabilities for full-length cDNA cloning and functional characterization of candidate genes. Financial terms were not announced.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.